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Introduction: DNA methylation of CpG islands within the promoter region of genes is an epigenetic modification
with an important role in the development of cancer and it is typically mediated by DNA methyltransferases
(DNMTs). In cancer cells, global hypomethylation of the genome as a whole and regional hypermethylation of CpG
islands have been reported. Four groups of DNMTs have been identified: DNMT1, DNMT2 (TRDMT1), DNMT3A and
DNMT3B. DNMT2 uses the catalytic mechanism of DNMTs, but does in fact methylate RNA. Little is known about
the significance of these genes in human breast cancer. In the study presented herein, we analyzed five distinct
DNMT single SNPs with regard to potential associations with breast cancer risk.
Case description: In this study, we genotyped 221 female Caucasian breast cancer patients and 221 female
Caucasian healthy controls, and we used five allele-specific real-time polymerase chain reaction (qPCR) assays. We
selected one locus within the DNMT1 gene and two loci within the DNMT3A and DNMT3B genes, respectively.
Statistics were calculated using the chi-squared and Fisher’s exact tests, and correlated with clinical parameters such
as age, diagnosis, histology, TNM stage, hormonal receptor status, human epidermal growth factor receptor 2
(HER2) status, response to treatment and survival. Statistically significant results were obtained for correlations with
the DNMT1 gene.
Discussion and Evaluation: Five genomic loci within the DNMT1, DNMT3A and DNMT3B genes were assessed.
Statistical significance (P = 0.030) was identified for DNMT1 SNP (A201G, rs2228612): six women within the control
group were GG homozygous (variant), while this mutation was absent in the breast cancer group.
Conclusions: We conclude that women with the DNMT1 SNP (A201G, rs2228612) GG homozygous genotype
(variant) have a lower risk of developing breast cancer compared to heterozygous or wildtype genotypes. To date,
alterations within the DNMT1 gene have not been reported to be associated with cancer in the Caucasian
population.
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Breast cancer is the most frequent malignancy in women
and it is also the leading cause of death among women
aged 40 to 50 years. Numerous risk factors of breast
cancer have been reported in the literature and the most* Correspondence: mahlknecht@gmx.de
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reproduction in any medium, provided the orrelevant factors are geographical variations, lifestyle, age
at the time of diagnosis, age at first pregnancy, age at
menarche, age at menopause and family history. BRCA1
and BRCA2 are genes associated with an increased risk
of developing breast cancer. Inherited mutations in the
p53 and PTEN genes have been observed in the context
of familial syndromes, Li-Fraumeni syndrome and
Cowden’s disease, which imply an increased risk of de-
veloping breast cancer. However, we need to consider
that both Li-Fraumeni syndrome and Cowden’s disease
are rare conditions [1]. Epigenetic events are importantral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Histone acetylation and/or methylation, as well as DNA
methylation, are epigenetic alterations which are revers-
ible. Histone modifications take place in eukaryotic cells,
while DNA methylation takes place in both eukaryotic
and prokaryotic cells. Both are relevant key elements
within the transcriptional regulatory machinery [3]. The
epigenetic modification of DNA methylation is typically
mediated by DNA methyltransferases (DNMTs). In can-
cer cells, there is a variation in 5-methylcytosine (m5C)
transmission along with global DNA hypomethylation
[4]. However, promoter CpG islands are typically
hypermethylated in many types of cancers, which can
lead to transcriptional silencing of the corresponding
genes [5,6]. Accordingly, the hypermethylation of gene
promoters or a hypomethylation of various parts of the
genome can contribute to the development of cellular
malignancy or autoimmune disease [7].
DNA methylation plays an important role in the con-
trol of gene expression in mammalian cells [8]. In breast
cancer, it has been shown that the methylation of pro-
moter regions in tumor suppressor genes can provide a
growth advantage to malignant cells. For example the
hypermethylation of the CpG islands in the estrogen re-
ceptor (ER)-promoter leads to the loss of ER protein ex-
pression. Therefore, the tumor is no longer under
estrogen control and this causes the growth of cancer
[9]. Nevertheless, with regard to human breast cancer,
little is known about the clinical and biological relevance
of DNMTs.Figure 1 The DNA methyltransferases (DNMTs) are divided into two g
maintenance of DNA methylation (b). De novo DNMTs (DNMT3A and DN
while the maintenance of methyltransferase DNMT1 attaches methyl groupTo date, four mammalian DNMTs have been identi-
fied: DNMT1, DNMT2 (TRDMT1), DNMT3A and
DNMT3B [10-12]. DNMT1 was the first methyltrans-
ferase to be found [13], and it is also the major and most
well characterized DNMT [14]. DNMTs can be divided
into two groups, which are responsible for de novo and
the maintenance of methylation (Figure 1) [15]. DNMT1
associates with the DNA replication fork and binds
methyl groups to hemimethylated DNA during replica-
tion for the maintenance of methylation in the genome.
The expression of DNMT1 is regulated by microRNAs
(in breast cancer tissues microRNAs are globally down-
regulated) [16] and the methyltransferase activity is
reduced by phosphorylation of DNMT1 [17]. Both
mechanisms are involved in the regulation of global
DNA methylation, but phosphorylation has been directly
associated with tumorigenesis [17]. However, the precise
role of DNMT1 functions in cancer cells is less well
understood, since alterations of this gene have not been
reported for cancer [18].
DNMT3A and DNMT3B are mainly involved in de
novo methylation and they are important for the gener-
ation of methylation patterns during embryogenesis [19].
De novo DNMTs methylate cytosine to m5C post-
replicatively from unmethylated DNA [3]. DNMT3A is
also able to methylate cytosine within CpA and CpT di-
nucleotides, although this enzyme is highly specific for
CpG methylation. However, the function of this DNA
modification is still unknown [20]. The two functionally
different groups of DNMTs may also interact with eachroups on the basis of their functional activities: de novo (a) and
MT3B) can create m5CpG dinucleotides from unmethylated DNA,
s to hemimethylated DNA during replication.
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represses gene expression through the deacetylation of
histone proteins, and thus a conformational change of
the chromatin architecture [3]. DNMT2 (TRDMT1) is
not only found in humans, but it is also found in other
mammalian and non-mammalian species, and exhibits
functional activities that are distinct from the other
DNMTs. DNMT2 is an active RNA methyltransferase
which is responsible for the methylation of the tRNAAsp
cytosine in position 38 (C38) [21]. It is the first example
of an RNA methyltransferase to take advantage of the
catalytic mechanisms of DNMT [22].
In order to assess the relevance of DNMT1, DNMT3A
and DNMT3B SNPs on DNMT gene expression and as-
sociated enzymatic activities, a number of gene loci were
identified in silico on the basis of the information
obtained from literature and SNP databases: DNMT1
SNP (A201G, rs2228612), DNMT3A SNPs (G301C,
rs34843713 and G301A, rs34191084) and DNMT3B
SNPs (C501T, rs406193 and G301A, rs35846833). In this
context, the DNMT2 (TRDMT1) gene has not been
considered, because human DNMT2 is an RNA
methyltransferase and this study was primarily focused
on genes coding for DNMTs, and because they have
been reported to play an important role in the develop-
ment of cancer [3].
With the study presented herein, it was our intention
to assess whether there was a correlation between
DNMT SNPs and the risk of developing breast cancer.
Case description
Blood and peripheral blood mononuclear cell (PBMC)
samples
In this study, we analyzed 221 DNA samples isolated
from PBMCs of female Caucasian breast cancer patients
and 221 DNA samples from female Caucasian healthy
donors. Patient samples were collected at the Depart-
ment of Obstetrics and Gynecology, Saarland University
Medical Center, Germany, between 2001 and 2010.
Control samples from healthy donors were collected at
the Central Laboratory, University of Heidelberg Med-
ical Center, Germany. All patients in the control group
were below the age of 30 years. Genomic DNA was
isolated from PBMCs and whole blood samples using
the NucleoSpin Blood kit (Macherey-Nagel, Düren,
Germany), in accordance with the manufacturer’s in-
structions. Analyses of DNA purity and quantification
were performed using a NanoDrop spectrophotometer
(Thermo Scientific, Waltham, MA, USA).
SNP selection
We identified SNPs within the coding and promoter re-
gions of the DNMT1, DNMT3A and DNMT3B genes via
in silico analyses using data from the National Centerfor Biotechnology Information (NCBI, Bethesda, MD,
USA), Applied Biosystems (Life Technologies, Carlsbad,
CA, USA), GeneCards and HapMap. These SNPs carried
the potential to affect the qualitative and quantitative
expression of the DNMTs mentioned, and to search for
potential associations with clinical parameters of breast
cancer patients (Additional file 1 and Table 1). Five
genomic loci corresponded to the criteria mentioned,
and were further analyzed in the group of female
Caucasian breast cancer patients and controls: DNMT1
SNP (A201G, rs2228612), DNMT3A SNPs (G301C,
rs34843713 and G301A, rs34191084) and DNMT3B
SNPs (C501T, rs406193 and G301A, rs35846833).
DNMT3B SNP (C501T, rs406193) was selected on the
basis of the publication by Cebrian et al. [2], which
showed a reduced risk of breast cancer for the T allele
(variant) within the DNMT3B gene. The DNMT1 SNP
(A201G, rs2228612) was recently analyzed in Chinese
women by Sun et al. [23] and they were able to demon-
strate breast cancer susceptibility in women with the GG
homozygote genotype (variant) [23]. The other SNPs
were selected on the basis of non-synonymous SNPs,
which could impact gene expression and/or protein
function, because they lead to a modified amino acid
product.
Genotyping
All samples of the selected tag SNPs were genotyped
by real-time polymerase chain reaction (qPCR) or
on TaqMan probes (Applied Biosystems, Darmstadt,
Germany). qPCRs were carried out on 10 ng of genomic
DNA using TaqMan universal PCR Master Mix (Applied
Biosystems, Darmstadt, Germany). Forward and reverse
primers were labeled VIC and FAM (designed by Ap-
plied Biosystems) in a 5 μl reaction (Table 2). The ampli-
fication conditions of TaqMan were as follows: 5
seconds at 50°C, followed by 10 minutes at 95°C and 12
seconds at 92°C, and finally 1 minute at 60°C. A total of
40 cycles were run and the completed PCRs were then
read in the end-point mode using the Allelic Discrimin-
ation Sequence Detector Software (Applied Biosystems).
A total of 221 DNA samples from female Caucasian
breast cancer patients and 221 DNA samples from fe-
male Caucasian healthy controls were assessed (Table 3).
Statistical methods
The Hardy-Weinberg equilibrium was tested using the
Simple Hardy-Weinberg Calculator by Michael H Court
(http://www.tufts.edu/~mcourt01/Documents/Court%
20lab%20-%20HW%20calculator.xls), by comparing the
observed and expected genotype frequencies for cases
and controls. Genotyping data generated for patients
and controls were correlated with clinical parameters
(age, diagnosis, histology, TNM status, ER status,
Table 1 Distribution of the clinical parameters
Clinical parameters Distribution
(%)
Age (years) 20 to 40 2.30
41 to 60 31.70
61 to >80 66.10







Mixed and other tumor
types
9.00







ER status Positive 82.40
Negative 17.60
PR status Positive 72.40
Negative 27.60










Survival Not detected 10.90
Alive 76.00
Death 13.10
DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal
growth factor receptor 2; LCIS, lobular carcinoma in situ; PR, progesterone
receptor; TNM, TNM Classification of Malignant Tumours.
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growth factor receptor 2 (HER2) status, response to
chemotherapy and survival) on the basis of the chi-
squared and Fisher’s exact tests. P values ≤0.05 were
considered to be statistically significant. All analyses
were performed using the statistical analysis software
SPSS Statistics Version 17 for Windows (IBM, Armonk,
NY, USA).Body which gave approval: Ärztekammer des Saarlandes,
Körperschaft des öffentlichen Rechts, Ethik-Kommission.
Reference number: 192/09.
Evaluation
The correlation of the genotyping results with clinical
parameters (age at the time of diagnosis, duration of dis-
ease, histology, TNM status, ER status, PR status, HER2
status, response of chemotherapy and survival) revealed
no statistical significance. The correlation of the geno-
typing results between cases and controls showed no co-
herence for the DNMT3A SNPs (G301C, rs34843713
and G301A, rs34191084) and DNMT3B SNP (G301A,
rs35846833). All women were homozygous for the
DNMT3A GG and DNMT3B GG genotype. Based on in-
formation obtained from the NCBI database, the fre-
quency of this polymorphism within the Caucasian
population was reported to be 1.4% for the DNMT3A
SNP (G301C, rs34843713) on the basis of 74 samples,
1.4% for the DNMT3B SNP (G301A, rs35846833) on the
basis of 74 samples and 1.5% for the DNMT3A SNP
(G301A, rs34191084) on the basis of 68 samples
(Table 3).
The DNMT3B SNP (C501T, rs406193) was analyzed
earlier as reported in the literature [2]. While Cebrian
et al. showed that there was a significant difference in
genotype distribution between breast cancer patients
and controls, with the T allele (variant) associated with a
reduced risk for breast cancer [2], our own analyses did
not show a statistically significant correlation between
the DNMT3B SNP and corresponding clinical parame-
ters. Our genotyping data comparing patients and con-
trols varied between 1.4% and 2.3% (Table 3), and were
clearly lower than the frequencies reported in the NCBI
database (12.5% for DNMT3B SNP (C501T, rs406193) in
central European Caucasian females) (Table 3). This ana-
lysis identified a statistical significance with a P value of
0.05.
We identified one additional statistically significant
correlation for DNMT1 SNP (A201G, rs2228612), which
appears to protect women against developing breast
cancer.
The P value of our results was 0.030, in accordance
with Fisher’s exact test. The genotyping results showed
that within the control group, 6 out of 221 women were
GG homozygous (variant), while the homozygous variant
genotype was not found in the group of breast cancer
patients (Figure 2 and Table 3). Therefore, our results
indicate that the G allele (variant) is associated with a re-
duced risk of developing breast cancer.
Discussion
In the case–control study presented herein, we correlated
genetic polymorphisms in three genes, DNMT1, DNMT3A
Table 2 Oligonucleotide primers
rs number Gene SNP AA Position Chromosome Target sequence Codon
rs2228612 DNMT1 A201G I/V Exon 19 5′-CAGAAA(C/T)CTGTGG-3′ 327
rs34843713 DNMT3A G301C R/P Exon 2 5′-AAGGGG(C/G)GATCAT-3′ 749
rs34191084 DNMT3A G301A G/S Exon 2 5′-CATCGC(C/T)TGCTTT-3′ 278
rs406193 DNMT3B C501T - Intron 20 5′-GAGACC(C/T)ATTAAT-3′ -
rs35846833 DNMT3B G301A R/C Exon 20 5′-CGAAGA(C/T)GCACAG-3′ 320
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risk of female Caucasians developing breast cancer.
The correlation with the SNPs in the DNMT genes
and the clinical parameters showed no statistical signifi-
cance. The identification of SNP alterations in associ-
ation with other risk factors for breast cancer could
provide an awareness of genetic variants that could lead
to an increased susceptibility of breast cancer [24].
Milne et al. failed to identify conclusive associations be-
tween the 12 selected SNPs and the age at menarche,
parity, age at first birth or body mass index (BMI) [24].
However, none of the DNMT SNPs tested in our study
were considered in the study by Milne et al. [24]. There-
fore, correlation of DNMT SNPs with clinical parameters
and/or environmental risk factors such as breastfeeding,
height, oral contraceptive and menopausal hormone
therapy use, alcohol consumption, cigarette smoking and
physical activity, could potentially yield significant in-
sights of breast cancer risk, which may then be consid-
ered for the design of further studies in the future [25].
Two out of five SNPs in the DNMT1, DNMT3A and
DNMT3B genes (DNMT3B SNP (C501T, rs406193) and
DNMT1 SNP (A201G, rs2228612)) reached statistical
significance (P = 0.05 and 0.03, respectively). For
DNMT3A, we assessed two SNPs (G301C, rs34843713
and G301A, rs34191084), which revealed the homozy-
gous wildtype allele in all samples that were studied











DNMT1 SNP 226 221a 88.50% 87.3
(A201G, rs2228612) 221b 81.4
DNMT3A SNP 74 221a 97.30% 100
(G301C, rs34843713) 221b 100
DNMT3A SNP 68 221a 97.10% 100
(G301A, rs34191084) 221b 100
DNMT3B SNP 120 221a 75% 69.7
(C501T, rs406193) 221b 77.8
DNMT3B SNP 74 221a 97.30% 100
(G301A, rs35846833) 221b 100
aResults of cases; bresults of controls. NCBI, National Center for Biotechnology Informprotein levels would have been of special interest, since
Ley et al. showed that DNMT3A mutations are highly
recurrent in patients with de novo acute myelogenous
leukemia (AML) and with an intermediate-risk cytogen-
etic profile, and these patients also had a significantly re-
duced survival [26]. Furthermore, there is also a
coherence between DNMT3A mutations and patients
with myelodysplastic syndrome (MDS), since Walter
et al. described the frequency of DNMT3A mutations in
patients with de novo MDS and their association with
secondary AML [27]. These mutations correlated with
overall reduced survival and accelerated progression to
AML [27]. AML and chronic myelogenous leukemia
(CML) cells in the acute phase also showed increased
expression levels for DNMT1, DNMT3A and DNMT3B
when compared to normal bone marrow cells. However,
such an over-expression of methyltransferases was not
observed in the chronic phase in CML cells [28]. Since
DNMT3B is able to mediate de novo DNA methylation
and has been shown to be over-expressed in numerous
types of cancer [14,28-31], this methyltransferase has
been postulated to be an important factor in cancer, and
it has been shown that DNMT3B polymorphisms are in
fact significantly associated with the risk of developing
lung cancer [32,33]. The level of DNMT3B protein is
significantly elevated in hypermethylated human breast
cancer cell lines, leading to an increased DNMT activity











%a 11.50% 12.7%a 5.80% 0%a
%b 15.8%b 2.7%b
%a 2.70% 0%a 1.40% 0%a
%b 0%b 0%b
%a 2.90% 0%a 1.50% 0%a
%b 0%b 0%b
%a 25% 28%a 12.50% 2.3%a
%b 20.8%b 1.4%b
%a 2.70% 0%a 1.40% 0%a
%b 0%b 0%b
ation.
Figure 2 Genotyping results. In this study, we genotyped 221 female Caucasian breast cancer patients and 221 female Caucasian healthy
controls. There was a statistical significance in the DNMT1 gene (DNMT1 SNP (A201G, rs2228612)) between cases and controls (P = 0.03). The
genotyping results in the DNMT3B gene (DNMT3B SNP (C501T, rs406193)) between cases and controls were also statistically significant (P = 0.05).
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vealed an association of over-expressed DNMT3B levels
and the development of breast cancer [8] and other ma-
lignancies [14,28-31].
In this study, we assessed two interesting DNMT3B
SNPs, of which DNMT3B SNP (G301A, rs35846833)
failed to be confirmed in the female Caucasian popula-
tion, showing only the wildtype genotype in all samples.
DNMT3B SNP (C501T, rs406193) showed a significant
difference among cases and controls (P value = 0.05)
with the T allele (variant) associated with a reduced risk
of developing breast cancer, while the statistical analysis
of the correlation with clinical parameters was not
significant. Montgomery et al. described a strong associ-
ation between the C allele of the DNMT3B promoter
polymorphism (C-149 T, rs2424913) and the risk of
developing breast cancer, compared to TT homozygotes
[34].
Ye et al. genotyped a total of 47 SNPs in the DNMT1
and DNMT3B genes, and the DNMT3B SNP (C501T,
rs406193), which was also analyzed in our study [35].
Twenty-two of these SNPs, including the DNMT3B SNP
(C501T, rs406193), were rejected from the analysis be-
cause either the minor allele frequencies were less than
0.005 in the study population or they were found to
deviate from the Hardy-Weinberg equilibrium in con-
trols. Thirteen SNPs in the DNMT3B gene (rs6058869,
rs242908, rs6119954, rs6141813, rs4911108, rs4911259,
rs910084, rs6088008, rs998382, rs4911110, rs6058893,
rs6058896, rs8118663) were included in the analysis, but
Ye et al. observed no association between these SNPs
and breast cancer among Chinese women [35], which
was inconsistent with the result of Cebrian et al. [2].
Cebrian et al. [2] showed statistical significance forDNMT3B SNP (C501T, rs406193) (odds ratio (OR) CT
versus CC = 0.85 (0.77 to 0.94); OR TT versus CC =
0.89 (0.64 to 1.23); P heterogeneity = 0.007; P trend =
0.003). This association was in accordance with our stat-
istical analysis, but Ye et al. could not confirm an appar-
ent association of the DNMT3B polymorphism (C501T,
rs406193) with the risk of breast cancer among Chinese
women, since this SNP was found to have a minor allele
frequency of less than 0.05 in the study population and
was excluded from the analysis [35]. Consequently, we
suggest that the mutation in the DNMT3B gene (C501T,
rs406193) is only relevant in the female Caucasian popu-
lation and not among the female Chinese population,
which might be due to the difference of the allele fre-
quency of this mutation between Caucasian (12.5%) and
Chinese patients (1.2%), according to the NCBI database
(since genetic mutations often vary between ethnic
groups).
DNMT1 is a maintenance methyltransferase which at-
taches methyl groups to hemimethylated DNA during
replication. To date, no genetic polymorphisms have
been reported for DNMT1 in association with breast
cancer in the female Caucasian population [18]. In the
study presented herein, we identified one DNMT1 SNP
(A201G, rs2228612) which could be relevant as a risk of
developing breast cancer in the female Caucasian popu-
lation. In relation to breast cancer risk, DNMT1 gene
polymorphisms have been solely reported in association
with sporadic infiltrating ductal breast cancer among
Chinese women [36]. Xiang et al. studied two SNPs in
the DNMT1 gene (T251C, rs16999593 and G301A,
rs2228611), and reported significance between the SNPs
and the PR and p53 status (p53-positive disease) [36]. Ye
et al. analyzed 12 SNPs in the DNMT1 gene (rs2116940,
Kullmann et al. Clinical Epigenetics 2013, 5:7 Page 7 of 8
http://www.clinicalepigeneticsjournal.com/content/5/1/7rs2336691, rs7253062, rs16999593, rs6511685, rs6511
677, rs8101866, rs2241531, rs10418707, rs10407514,
rs4804122, rs11085587), but they did not find any appar-
ent association of DNMT1 mutation with the risk of
breast cancer among Chinese women [35]. A recent art-
icle by Sun et al. found evidence of an association of
breast cancer risk among Chinese Han women from
South China with SNPs in the DNMT1 gene [23]. For
DNMT1 SNP rs2228612, the frequency of the GG geno-
type (variant) of rs2228612 was higher in cases compared
to controls (22.5% versus 14.5%) (OR AG versus GG =
1.71 (1.06 to 2.78); OR GG versus AA 1.75 (1.13 to 2.72);
P heterogeneity = 0.044; P trend = 0.013) [23]. These re-
sults contradict our own observations, which imply ethnic
differences still remain to be further elucidated.
In this study, we were able to show a significant asso-
ciation between the DNMT1 gene polymorphism
(A201G, rs2228612) and the risk of breast cancer in the
female Caucasian population. The correlation of cases
and controls showed a statistical significance with a P
value of 0.030 (Fisher’s exact test), whereas the statistical
analyses of frequency differences between cases and clin-
ical parameters revealed no significant results. While six
female controls were GG homozygous (variant), there
were no females in the group of breast cancer patients
with the GG homozygous genotype (variant). Therefore,
our results show that the DNMT1 gene polymorphism
(A201G, rs2228612) with the g-allele (variant) is associ-
ated with a reduced risk of developing breast cancer.Conclusion
In conclusion, our results showed that the two DNMT
3A SNPs (G301C, rs34843713 and G301A, rs34191084)
and the DNMT3B SNP (G301A, rs35846833) do not
exist in the female Caucasian population. Otherwise, we
could demonstrate a statistical significance in the differ-
ences of allele frequencies of cases and controls of the
DNMT3B SNP (C501T, rs406193), like in the study of
Cebrian et al. [2].
Finally, we identified a significant association of the
DNMT1 SNP (A201G, rs2228612) variant in the correl-
ation of cases and controls. Women with the G allele
(variant) show a lower risk of developing breast cancer.
The diagnostic impact of this new marker needs to be
validated in further clinical studies in larger populations
and within different ethnic groups, but it presents a fur-
ther step towards a more individualized diagnosis.
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